The Library
Methylglyoxal-induced dicarbonyl stress in aging and disease : first steps towards glyoxalase 1-based treatments
Tools
Tools
Tools
Rabbani, Naila, Xue, Mingzhan and Thornalley, Paul J. (2016) Methylglyoxal-induced dicarbonyl stress in aging and disease : first steps towards glyoxalase 1-based treatments. Clinical Science, 130 (19). pp. 1677-1696. doi:10.1042/CS20160025
Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1042/CS20160025
Abstract
Dicarbonyl stress is the abnormal accumulation of dicarbonyl metabolites leading to increased protein and DNA modification contributing to cell and tissue dysfunction in aging and disease. It is produced by increased formation and/or decreased metabolism of dicarbonyl metabolites. MG (methylglyoxal) is a dicarbonyl metabolite of relatively high flux of formation and precursor of the most quantitatively and functionally important spontaneous modifications of protein and DNA clinically. Major MG-derived adducts are arginine-derived hydroimidazolones of protein and deoxyguanosine-derived imidazopurinones of DNA. These are formed non-oxidatively. The glyoxalase system provides an efficient and essential basal and stress-response-inducible enzymatic defence against dicarbonyl stress by the reduced glutathione-dependent metabolism of methylglyoxal by glyoxalase 1. The GLO1 gene encoding glyoxalase 1 has low prevalence duplication and high prevalence amplification in some tumours. Dicarbonyl stress contributes to aging, disease and activity of cytotoxic chemotherapeutic agents. It is found at a low, moderate and severe level in obesity, diabetes and renal failure respectively, where it contributes to the development of metabolic and vascular complications. Increased glyoxalase 1 expression confers multidrug resistance to cancer chemotherapy and has relatively high prevalence in liver, lung and breast cancers. Studies of dicarbonyl stress are providing improved understanding of aging and disease and the basis for rational design of novel pharmaceuticals: glyoxalase 1 inducers for obesity, diabetes and cardiovascular disease and glyoxalase 1 inhibitors for multidrug-resistant tumours. The first clinical trial of a glyoxalase 1 inducer in overweight and obese subjects showed improved glycaemic control, insulin resistance and vascular function.
| Item Type: | Journal Article | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Divisions: | Faculty of Medicine > Warwick Medical School | ||||||||
| Journal or Publication Title: | Clinical Science | ||||||||
| Publisher: | Portland Press | ||||||||
| ISSN: | 0143-5221 | ||||||||
| Official Date: | 23 August 2016 | ||||||||
| Dates: |
|
||||||||
| Volume: | 130 | ||||||||
| Number: | 19 | ||||||||
| Page Range: | pp. 1677-1696 | ||||||||
| DOI: | 10.1042/CS20160025 | ||||||||
| Status: | Peer Reviewed | ||||||||
| Publication Status: | Published | ||||||||
| Access rights to Published version: | Restricted or Subscription Access |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
